Brought to you by 
Midatech licenses Novartis' panobinostat for brain cancers
14 Mar 2019
Executive Summary
Midatech Pharma PLC licensed worldwide rights to Novartis AG's panobinostat for diffuse intrinsic pontine glioma (DIPG), an ultra-rare childhood brain cancer, and potentially glioblastoma (GBM).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Midatech licenses Novartis' panobinostat for brain cancers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice